Brimonidine Tartrate for the Treatment of Injection Related Erythema

NCT02568111 — Phase 4, Withdrawn, Biogen

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Brimonidine Tartrate for the Treatment of Injection Related Erythema Associated With Sub-cutaneous Administration of Peginterferon Beta-1a (BRITE)

Registry	NCT02568111, acronym BRITE
Status	Withdrawn
Phase	Phase 4
Study type	Interventional; randomized, parallel, masking: triple, supportive care
Sponsor	Biogen (Industry)
Conditions	Relapsing-Remitting Multiple Sclerosis (RRMS)
Interventions	peginterferon beta-1a, brimonidine tartrate, Vehicle Gel (Drug)
Dates	start 2016-02-01, primary completion 2016-08-01 (estimated), completion 2016-08-01 (estimated), first posted 2015-10-05, last updated 2016-04-25

-Summary

The primary objective of this study is to evaluate the Injection Related Erythema (IRE) mitigation effect of a single administration of brimonidine tartrate in comparison with a vehicle gel (placebo).

The secondary study objectives are to evaluate the IRE mitigation effect of a single administration of brimonidine tartrate in comparison with a vehicle gel on a more stringent definition scale, in accordance with the primary endpoint of the original brimonidine pivotal trials and participants' satisfaction with the overall appearance of their skin.

Expand all sections · Collapse all

+Detailed description

Participants naïve to treatment with subcutaneous (SC) interferons or oral Disease Modifying Therapy (DMT) who are about to start PLEGRIDY PEN therapy will be screened for participation in this Phase IV trial. Participants will remain on Plegridy therapy as prescribed by their physician. Plegridy will not be provided to participants by Biogen as a part of this study.

+Arms and interventions

Arm	Type	Interventions	Description
brimonidine tartrate	Experimental	Drug: peginterferon beta-1a; Drug: brimonidine tartrate	Participants will apply gel to injection site erythema area after IRE development post peginterferon beta-1a injection
Vehicle Gel	Placebo comparator	Drug: peginterferon beta-1a; Drug: Vehicle Gel	Participants will apply vehicle gel placebo to injection site erythema area after IRE development post peginterferon beta-1a injection

peginterferon beta-1a (Drug), also known as PEGylated Interferon Beta-1a, PEG IFN β-1a, Plegridy, BIIB017: SC administration as prescribed by the physician- initial dose of 63 μg followed by 94 μg dose on day 15 and 125 μg on day 29
brimonidine tartrate (Drug), also known as Mirvaso: Applied to injection site as specified in the treatment arm. Commercially available Mirvaso (Brimonidine tartrate) gel will be provided by Galderma.
Vehicle Gel (Drug): Matched placebo applied to injection site as specified in the treatment arm. Matching vehicle gel will be provided by Galderma.

+Outcome measures

Primary outcomes

Change in either Clinician's Erythema Assessment (CEA) or Patient Erythema Self-Assessment (PSA) scale measured as at least 1-grade improvement on CEA and/or at least 1-grade improvement on PSA scale assessed by the physician and participant [Before and after 6 hours of gel application]: Investigator will evaluate participant's erythema (redness) at the site of injection on a scale of 0 (clear) to 4 (severe) with higher scores indicating higher levels of erythema. Participants rate erythema at the site of injection on a scale of 0 (clear) to 4 (severe) with higher scores indicating higher levels of erythema.

Secondary outcomes

Composite change in both CEA and PSA scale measured as at least 1-grade improvement on CEA and 1-grade improvement on PSA respectively [Before and after 6 hours of gel application]: This composite endpoint is considered to be sensitive enough and directly correlated with participants' satisfaction therapy outcomes.
Composite change in both CEA and PSA scale measured as at least 2-grade improvement on CEA and 2-grade improvement on PSA [Before and after 6 hours of gel application]
Participant's self-assessment of satisfaction with the overall appearance of their skin by using a Patient's Assessment of Appearance (PAA) grading scale [Before and after 6 hours of gel application]: PAA satisfaction score will describe how satisfied the participants are with the overall appearance of skin on a scale of 0 (very satisfied) to 4 (very dissatisfied).

+Eligibility

Sex: All, ages: 18 Years to any

Key Inclusion Criteria:

* RRMS patients naïve to treatment with SC interferon or oral and/or IV DMT for which PLEGRIDY is deemed necessary by the treating physician.
* Patient willing and able to complete PSA and PAA questionnaires with minimal assistance.

Key Exclusion Criteria:

* Known allergy to any interferon or any component of peginterferon beta-1a.
* Patients with hypersensitivity to Brimonidine topical gel.
* Patients with other skin disorders.
* History of previous treatment with Brimonidine tartrate.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

+Investigators

Medical Director, Study director, Biogen

+Funding

NIH grants: 2015